PFSA
Profusa, Inc. Common Stock NASDAQ Listed Jul 14, 2025$0.90
-5.34%
vs $0.95
Mkt Cap $4.0M
52w Low $0.81
0.0% of range
52w High $1297.50
50d MA $3.02
200d MA $103.28
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-0.6x
ROE
134.4%
P/FCF
-0.0x
RSI (14)
24.70
ATR (14)
$0.11
Beta
0.26
50d MA
$3.02
200d MA
$103.28
Avg Volume
507.4K
A digital-health company developing tissue-integrating biosensors (e.g. the Lumee™ Oxygen Platform) to continuously monitor body chemistry and provide AI-powered health insights, targeting chronic conditions such as diabetes and critical limb ischemia
CIK (SEC)
Phone
415 655 9861
5959 Horton Street, Suite 450, Emeryville, CA 94608 · EmeryVille, CA 94608 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | AMC | — | -6.95 | — | 0.58 | +1.8% | +31.0% | +144.1% | -32.4% | -2.4% | -13.9% | — |
| Nov 19, 2025 | AMC | — | -0.70 | — | 12.68 | -7.8% | -19.6% | +1.9% | +8.4% | +1.4% | +5.2% | — |
| Aug 14, 2025 | AMC | — | -1.53 | — | 40.73 | +5.0% | -8.1% | +12.7% | -8.0% | +0.1% | -10.1% | — |
| Mar 31, 2025 | AMC | — | -6.21 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2024 | AMC | — | -96.73 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2024 | AMC | — | -96.61 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2024 | AMC | — | -0.91 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2024 | AMC | — | -5.46 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | 2.94 | — | — | — | — | — | — | — | — | — |
No analyst ratings available.
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | HRT FINANCIAL LP10% | — | Sell | 42,411 | $0.89 | $38K | 74,198 | — | — |
| Aug 12, 2026 | HRT FINANCIAL LP10% | — | Buy | 5,585 | $0.96 | $5K | 116,609 | — | — |
| Aug 11, 2026 | HRT FINANCIAL LP10% | — | Sell | 2,280 | $0.97 | $2K | 111,024 | -1.49% | — |
| Aug 10, 2026 | HRT FINANCIAL LP10% | — | Buy | 4,016 | $0.94 | $4K | 113,304 | -1.49% | — |
| Aug 7, 2026 | HRT FINANCIAL LP10% | — | Sell | 924 | $0.95 | $874 | 109,288 | +4.90% | — |
| Aug 6, 2026 | HRT FINANCIAL LP10% | — | Buy | 926 | $0.94 | $873 | 110,212 | +4.90% | — |
| Aug 5, 2026 | HRT FINANCIAL LP10% | — | Sell | 383 | $0.94 | $361 | 109,286 | +4.90% | — |
| Aug 4, 2026 | HRT FINANCIAL LP10% | — | Buy | 1,368 | $0.95 | $1K | 109,669 | -0.20% | -2.03% |
| Aug 3, 2026 | HRT FINANCIAL LP10% | — | Buy | 14,556 | $0.96 | $14K | 108,301 | -0.20% | -2.03% |
| Jul 31, 2026 | HRT FINANCIAL LP10% | — | Buy | 8,811 | $1.05 | $9K | 93,745 | +1.81% | -2.47% |
| Jul 30, 2026 | HRT FINANCIAL LP10% | — | Buy | 1,063 | $1.01 | $1K | 84,934 | +1.81% | -2.47% |
| Jul 29, 2026 | HRT FINANCIAL LP10% | — | Buy | 1,310 | $1.01 | $1K | 83,871 | +0.00% | -0.20% |
8-K · 8.01
!! High
Profusa, Inc. -- 8-K 8.01: Material Event / Announcement
Aug 14
8-K · 5.02
!!! Very High
Profusa, Inc. -- 8-K 5.02: Executive Change
Jack Stover's appointment as Executive Chairman and CEO of Profusa signals leadership continuity as the company prepares to close a significant transaction.
Jul 27
8-K
Profusa, Inc. -- 8-K Filing
Jun 23
8-K · 8.01
!! High
Profusa, Inc. -- 8-K 8.01: Material Event / Announcement
Ascent's waiver of mandatory prepayment provisions on Advance Notices provides Profusa with improved liquidity flexibility by deferring payment obligations until share delivery occurs.
Jun 8
8-K · 1.01
!! High
Profusa, Inc. -- 8-K 1.01: Material Agreement
Profusa modified its asset purchase agreement, indicating potential changes to deal terms, asset scope, or closing conditions that could affect the transaction's value or timeline for shareholders.
May 26
8-K · 8.01
!! High
Profusa, Inc. -- 8-K 8.01: Material Event / Announcement
May 18
8-K · 8.01
!! High
Profusa, Inc. -- 8-K 8.01: Material Event / Announcement
May 15
8-K · 8.01
!! High
Profusa, Inc. -- 8-K 8.01: Material Event / Announcement
Profusa received a Nasdaq compliance exception allowing continued listing while meeting specified requirements, though the exchange retains discretion to reconsider terms based on future developments or material events.
May 8
8-K · 1.01
! Medium
Profusa, Inc. -- 8-K 1.01: Financing / Debt Agreement
Profusa secured financing through an agreement with Ascent Partners Fund LLC, providing capital to support operations and strategic initiatives for the wearable biotech company.
Apr 24
8-K · 8.01
!! High
Profusa, Inc. -- 8-K 8.01: Material Event / Announcement
Profusa (PFSA) entered into a license agreement, though specific terms and strategic implications require review of the full press release filing.
Feb 13
8-K · 8.01
!! High
Profusa, Inc. -- 8-K 8.01: Material Event / Announcement
Profusa announced a reverse stock split affecting its share structure and per-share financial metrics, which may impact investor valuations and trading dynamics while potentially consolidating outstanding shares to improve stock price appearance.
Feb 5
8-K
Profusa, Inc. -- 8-K Filing
Profusa appointed a new independent registered public accounting firm to audit its financial statements for the year ending December 31, 2025.
Feb 2
Institutional (13F) — Top 3
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Citadel Advisors Llc | 30,844 | $16K | New | Mar 2026 |
| 2 | Ubs Group Ag | 665 | $337 | New | Mar 2026 |
| 3 | Fmr Llc | 13 | $7 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 1,490 | $2K | Feb 2026 |
| 2 | Fidelity Nasdaq Composite Index Fund | 211 | $219 | Feb 2026 |
| 3 | Fidelity Series Total Market Index Fund | 217 | $77 | May 2026 |
Valuation
Market Cap
$4.0M
Enterprise Value
$6.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.00x
P/B
—
P/S
—
P/FCF
-0.02x
EV/EBITDA
—
Shares Out
335K
Financials (TTM)
Revenue
$0
Net Income
-$42.4M
EBITDA
-$40.7M
Free Cash Flow
-$16.3M
Op Cash Flow
-$16.2M
EPS Basic
$-107.01
EPS Diluted
$-179.82
EPS Forward
—
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$3.8M
Total Liab.
$30.4M
Total Equity
-$26.7M
Cash
$1.8M
LT Debt
$7.9M
Book Value/Sh
$-79.63
Debt/Equity
-0.56x
Current Ratio
0.17
Quick Ratio
0.17
Returns & Growth
ROE
134.4%
ROA
-948.9%
ROIC
114.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
-409.6%
Price Returns
2W
-15.1%
1M
-52.4%
3M
-91.9%
6M
-98.2%
12M
-99.9%
Technicals
52W High
$1297.50
52W Low
$0.81
50d MA
$3.02
200d MA
$103.28
RSI (14)
24.70
ATR (14)
$0.11
Beta
0.26
Avg Volume
507K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 26, 2026 7:25pm
· Source: financialmodelingprep.com